Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen

被引：0
|
作者：
Lintermans, A.
Dieudonne, A. S.
Vanderhaegen, J. [1 ]
Henry, N. L. [2 ]
Wildiers, H. [3 ]
Paridaens, R. [3 ]
Christiaens, M. R. [3 ]
Smeets, A. [3 ]
Leunen, K. [3 ]
Neven, P. [3 ]
机构：
[1] Katholieke Univ Leuven Hosp, Gynecol Multidisciplinary Breast Ctr, Louvain, Belgium
[2] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[3] Katholieke Univ Leuven Hosp, Multidisciplinary Breast Ctr, Louvain, Belgium
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [1] Prospective assessment of loss of grip strength by baseline BMI in breast cancer patients receiving adjuvant aromatase inhibitors or tamoxifen
    Lintermans, A.
    Van Asten, K.
    Wildiers, H.
    Paridaens, R.
    Weltens, C.
    Van Limbergen, E.
    Smeets, A.
    Leunen, K.
    Christiaens, M. R.
    Neven, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S99 - S99
  • [2] A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen.
    Lintermans, A.
    Dieudonne, A-S
    Vanderhaegen, J.
    Henry, N. L.
    Laenen, A.
    Wildiers, H.
    Paridaens, R.
    Christiaens, M-R
    Smeets, A.
    Leunen, K.
    Amant, F.
    Vergote, I.
    Neven, P.
    CANCER RESEARCH, 2011, 71
  • [3] A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI
    A. Lintermans
    K. Van Asten
    H. Wildiers
    A. Laenen
    R. Paridaens
    C. Weltens
    J. Verhaeghe
    D. Vanderschueren
    A. Smeets
    E. Van Limbergen
    K. Leunen
    M. R. Christiaens
    P. Neven
    Breast Cancer Research and Treatment, 2014, 146 : 109 - 116
  • [4] A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI
    Lintermans, A.
    Van Asten, K.
    Wildiers, H.
    Laenen, A.
    Paridaens, R.
    Weltens, C.
    Verhaeghe, J.
    Vanderschueren, D.
    Smeets, A.
    Van Limbergen, E.
    Leunen, K.
    Christiaens, M. R.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (01) : 109 - 116
  • [5] Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
    Dackus, Gwen M. H. E.
    Jozwiak, Katarzyna
    Sonke, Gabe S.
    van der Wall, Elsken
    van Diest, Paul J.
    Siesling, Sabine
    Hauptmann, Michael
    Linn, Sabine C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (11): : 1506 - 1514
  • [6] Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
    Holm Eggemann
    Atanas Ignatov
    Bobbie J. Smith
    Udo Altmann
    Gunter von Minckwitz
    Freidrich W. Röhl
    Mark Jahn
    Serban-Dan Costa
    Breast Cancer Research and Treatment, 2013, 137 : 465 - 470
  • [7] Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
    Eggemann, Holm
    Ignatov, Atanas
    Smith, Bobbie J.
    Altmann, Udo
    von Minckwitz, Gunter
    Roehl, Freidrich W.
    Jahn, Mark
    Costa, Serban-Dan
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 465 - 470
  • [8] RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
    Klar, Natalie
    Adams, Sylvia
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (01): : 165 - 166
  • [9] Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
    Kubilay Karaboyun
    Eyyup Cavdar
    Yakup Irıagac
    Abdussamet Celebı
    Tanju Kapagan
    Ilkay Gulturk
    Ozden Demır
    Okan Avcı
    Erdogan Selcuk Seber
    Supportive Care in Cancer, 2023, 31
  • [10] Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
    Karaboyun, Kubilay
    Cavdar, Eyyup
    Iriagac, Yakup
    Celebi, Abdussamet
    Kapagan, Tanju
    Gulturk, Ilkay
    Demir, Ozden
    Avci, Okan
    Seber, Erdogan Selcuk
    SUPPORTIVE CARE IN CANCER, 2023, 31 (06)
12345